AbbreviationsAFPalpha‐fetoproteinBCLCBarcelona Clinic Liver CancerDCPdes‐gamma‐carboxyprothrombinHCChepatocellular carcinomaLDLTliving donor liver transplantationLRTlocal‐regional therapyLTliver transplantationFor patients with hepatocellular carcinoma (HCC) exceeding the Milan criteria, survival after liver transplantation (LT) incrementally decreases with increasing tumor size and number. The allocation system for deceased donors in the United States is largely restricted to HCC within Milan criteria and does not accommodate to even modest expansion of tumor size. Wait‐list dropout rates remain substantial even for HCC within Milan criteria in long wait‐time regions. Living donor liver transplantation (LDLT) has been performed for patients with HCC beyond Milan criteria adhering to the principle that the risk to the donor is justified by the expectation of an acceptable outcome for the recipient (double equipoise). However, the boundaries of tumor size and number to be considered for LDLT have varied widely among centers without a consensus based on reproducible data. Furthermore, the minimal acceptable survival threshold after LDLT has not been well defined.In this issue of Liver Transplantation, Llovet et al. from the Barcelona Clinic Liver Cancer (BCLC) group report their longterm results up to 10 years following LDLT for HCC beyond Milan criteria in a prospectively applied protocol. The study cohort met the proposed BCLC extended criteria (1
Liver Transplantation – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud